Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities

被引:29
作者
Boiocchi, Leonardo [1 ,2 ]
Orazi, Attilio [1 ]
Ghanima, Waleed [3 ,4 ]
Arabadjief, Melissa [1 ]
Bussel, James B. [3 ]
Geyer, Julia Turbiner [1 ]
机构
[1] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA
[2] Univ Milan, Sch Med, Dept Med Surg & Dent, Pathol Unit,Fdn IRCCS Ca Granda Osped Maggiore Po, Milan, Italy
[3] Weill Cornell Med Coll, Dept Pediat, New York, NY 10065 USA
[4] Ostfold Hosp Trust, Dept Med, Fredrikstad, Norway
关键词
bone marrow biopsy; c-MPL; megakaryocyte; myeloproliferative marrow; primary immune thrombocytopenia; thrombopoietin receptor agonists; POLYCYTHEMIA-VERA; CELLS; MYELOFIBROSIS; PURPURA; DIFFERENTIATION; MEGAKARYOCYTES; JAK2; MICE; PATHOPHYSIOLOGY; STANDARDIZATION;
D O I
10.1038/modpathol.2011.128
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Primary immune thrombocytopenia is an acquired autoimmune disorder characterized by platelet count of <100 x 10(9)/l in the absence of other causes of thrombocytopenia. Primary immune thrombocytopenia is defined as 'chronic' when it has been present for more than 12 months without spontaneous remission or maintenance of complete response to therapy. Recently, thrombopoietin receptor agonists became available for treatment of chronic primary immune thrombocytopenia. Anecdotal reports have raised concerns about a possible association between therapy with thrombopoietin receptor agonists and an increase in bone marrow fibrosis. To investigate this association we studied eight patients with primary immune thrombocytopenia in detail comparing fibrosis and other morphological features in pre-therapy and on-therapy bone marrow biopsies, with the longest follow-up reported to date. A slight but significant increase to MF-1 in reticulin fibrosis was observed during therapy, but collagen was never present. On-therapy bone marrows were hypercellular due to panmyelosis with increased trilineage hematopoiesis. Megakaryocytes were increased in number, with acquisition of evident pleomorphism, nuclear hyperlobulation and tendency in some cases to form clusters. The overall picture of the on-therapy marrows was characterized by myeloproliferative neoplasm-like features, resembling essential thrombocythemia or occasionally early primary myelofibrosis. As thrombopoietin receptor agonists are becoming a mainstream treatment for primary immune thrombocytopenia, general pathologists and especially hematopathologists need to be aware of the characteristic morphological changes associated with use of these therapeutic agents, in order to avoid misdiagnosis of a myeloid neoplasm. Modern Pathology (2012) 25, 65-74; doi:10.1038/modpathol.2011.128; published online 12 August 2011
引用
收藏
页码:65 / 74
页数:10
相关论文
共 41 条
  • [1] Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients
    Aleem, Aamer
    Alaskar, Ahmed S.
    Algahtani, Farja
    Rather, Mushtaq
    Almahayni, Muhamad Hitham
    Al-Momen, Abdulkarim
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (02) : 283 - 288
  • [2] Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-mpl
    Alexander, WS
    Roberts, AW
    Nicola, NA
    Li, RL
    Metcalf, D
    [J]. BLOOD, 1996, 87 (06) : 2162 - 2170
  • [3] BAUERMEISTER DE, 1971, AM J CLIN PATHOL, V56, P24
  • [4] BECKMAN EN, 1990, ARCH PATHOL LAB MED, V114, P1241
  • [5] Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
    Bussel, James B.
    Cheng, Gregory
    Saleh, Mansoor N.
    Psaila, Bethan
    Kovaleva, Lidia
    Meddeb, Balkis
    Kloczko, Janusz
    Hassani, Habib
    Mayer, Bhabita
    Stone, Nicole L.
    Arning, Michael
    Provan, Drew
    Jenkins, Julian M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) : 2237 - 2247
  • [6] AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
    Bussel, James B.
    Kuter, David J.
    George, James N.
    McMillan, Robert
    Aledort, Louis M.
    Conklin, George T.
    Lichtin, Alan E.
    Lyons, Roger M.
    Nieva, Jorge
    Wasser, Jeffrey S.
    Wiznitzer, Israel
    Kelly, Reggie
    Chen, Chien-Feng
    Nichol, Janet L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (16) : 1672 - 1681
  • [7] Traditional and New Approaches to the Management of Immune Thrombocytopenia: Issues of When and Who to Treat
    Bussel, James B.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (06) : 1329 - +
  • [8] Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
    Bussel, James B.
    Kuter, David J.
    Pullarkat, Vinod
    Lyons, Roger M.
    Guo, Matthew
    Nichol, Janet L.
    [J]. BLOOD, 2009, 113 (10) : 2161 - 2171
  • [9] IMMUNOELECTRON MICROSCOPY CHARACTERIZATION OF HUMAN BONE-MARROW STROMAL CELLS WITH ANTI-NGFR ANTIBODIES
    CANEVA, L
    SOLIGO, D
    CATTORETTI, G
    DEHARVEN, E
    DELILIERS, GL
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 1995, 21 (02) : 73 - 85
  • [10] Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice
    Chagraoui, H
    Komura, E
    Tulliez, M
    Giraudier, S
    Vainchenker, W
    Wendling, F
    [J]. BLOOD, 2002, 100 (10) : 3495 - 3503